BACKGROUND: For patients with ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI), rapid restoration of coronary blood flow is the primary therapeutic goal. Because of the acute nature of this clinical presentation, bleeding risks may not be adequately evaluated, limiting the use of drug-eluting stents, since premature discontinuation of antiplatelet therapy strongly predicts stent thrombosis. We evaluated angiographic and clinical results of non-drug-eluting carbon-coated stents. METHODS: In this prospective observational study, angiographic and clinical 6-mo results of a carbon-coated stent for treatment of acute lesions in native coronary arteries were evaluated. Angiographic main outcome measures included in-stent late loss and binary restenosis rate. Major adverse cardiac events (MACEs) were defined as any death, Q-wave myocardial infarction (MI), and target lesion revascularization. RESULTS: We included 320 patients with STEMI (n = 205) or NSTEMI (n = 115) with 360 lesions. Reference vessel diameter was 2.93 +/- 0.53 mm and stented length 22.7 +/- 13.8 mm. Angiographic follow-up was available in 220 of 360 lesions (61%). In-stent late loss was 0.69 +/- 0.75 mm, with a binary restenosis rate of 19.1%. For the total segment late loss was 0.74 +/- 0.77 mm and binary restenosis rate 21.4%. Clinical follow-up for 97.4% of discharged patients was available. Hierarchical MACEs were death in 14 patients (4.4%), Q-wave MI in 3 patients (0.9%), and target lesion revascularization in 39 patients (12.2%). CONCLUSION: In this prospective, observational study, the use of a carbon-coated stent for treatment of lesions in patients with STEMI or NSTEMI was associated with a low late loss, translating into a low binary angiographic restenosis rate within a 6-mo follow-up. 2008 Wiley Periodicals, Inc.
BACKGROUND: For patients with ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI), rapid restoration of coronary blood flow is the primary therapeutic goal. Because of the acute nature of this clinical presentation, bleeding risks may not be adequately evaluated, limiting the use of drug-eluting stents, since premature discontinuation of antiplatelet therapy strongly predicts stent thrombosis. We evaluated angiographic and clinical results of non-drug-eluting carbon-coated stents. METHODS: In this prospective observational study, angiographic and clinical 6-mo results of a carbon-coated stent for treatment of acute lesions in native coronary arteries were evaluated. Angiographic main outcome measures included in-stent late loss and binary restenosis rate. Major adverse cardiac events (MACEs) were defined as any death, Q-wave myocardial infarction (MI), and target lesion revascularization. RESULTS: We included 320 patients with STEMI (n = 205) or NSTEMI (n = 115) with 360 lesions. Reference vessel diameter was 2.93 +/- 0.53 mm and stented length 22.7 +/- 13.8 mm. Angiographic follow-up was available in 220 of 360 lesions (61%). In-stent late loss was 0.69 +/- 0.75 mm, with a binary restenosis rate of 19.1%. For the total segment late loss was 0.74 +/- 0.77 mm and binary restenosis rate 21.4%. Clinical follow-up for 97.4% of discharged patients was available. Hierarchical MACEs were death in 14 patients (4.4%), Q-wave MI in 3 patients (0.9%), and target lesion revascularization in 39 patients (12.2%). CONCLUSION: In this prospective, observational study, the use of a carbon-coated stent for treatment of lesions in patients with STEMI or NSTEMI was associated with a low late loss, translating into a low binary angiographic restenosis rate within a 6-mo follow-up. 2008 Wiley Periodicals, Inc.
Authors: Jürgen Pache; Adnan Kastrati; Julinda Mehilli; Helmut Schühlen; Franz Dotzer; Jörg Hausleiter; Martin Fleckenstein; Franz Josef Neumann; Ulrich Sattelberger; Claus Schmitt; Martina Müller; Josef Dirschinger; Albert Schömig Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: Gian B Danzi; Cinzia Capuano; Marco Sesana; Roberto Baglini; Antonio L Bartorelli; Daniela Trabattoni; Angela Migliorini; David Antoniucci Journal: J Invasive Cardiol Date: 2004-11 Impact factor: 2.022
Authors: A Kastrati; J Mehilli; J Dirschinger; F Dotzer; H Schühlen; F J Neumann; M Fleckenstein; C Pfafferott; M Seyfarth; A Schömig Journal: Circulation Date: 2001-06-12 Impact factor: 29.690
Authors: G W Stone; B R Brodie; J J Griffin; C Costantini; M C Morice; F G St Goar; P A Overlie; J J Popma; J McDonnell; D Jones; W W O'Neill; C L Grines Journal: Circulation Date: 1999-03-30 Impact factor: 29.690
Authors: David Antoniucci; Alfredo Rodriguez; Albrecht Hempel; Renato Valenti; Angela Migliorini; Federico Vigo; Guido Parodi; Carlos Fernandez-Pereira; Guia Moschi; Antonio Bartorelli; Giovanni Maria Santoro; Leonardo Bolognese; Antonio Colombo Journal: J Am Coll Cardiol Date: 2003-12-03 Impact factor: 24.094
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: Helmut Schühlen; Adnan Kastrati; Julinda Mehilli; Jörg Hausleiter; Jürgen Pache; Josef Dirschinger; Albert Schömig Journal: Am Heart J Date: 2004-02 Impact factor: 4.749
Authors: Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Alexander Grenadyorov; Andrey Solovyev; Konstantin Oskomov; Ekaterina Porokhova; Konstantin Brazovskii; Anna Gorokhova; Temur Nasibov; Larisa Litvinova; Igor Khlusov Journal: Materials (Basel) Date: 2022-06-15 Impact factor: 3.748